We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App





Sekisui Diagnostics Displays Full Range of Clinical Chemistry, Point-of-Care, and Biochemical Solutions

By LabMedica International staff writers
Posted on 19 Nov 2025

At MEDICA 2025, Sekisui Diagnostics is presenting a broad lineup of in-vitro diagnostic products spanning clinical chemistry reagents, point-of-care testing solutions, enzymes and specialty biochemicals, biopharmaceutical services, and blood collection tube raw materials. More...

Exhibiting in Hall 1, Stand D57, the company draws on more than 40 years of global diagnostics expertise to support physicians, hospitals, laboratories, and decentralized testing environments.

At the booth, visitors can explore the OSOM rapid-test family, which provides fast, lateral-flow diagnostics for a wide range of infectious diseases, including influenza, Group A Strep, and Trichomonas vaginalis. For clinical chemistry, Sekisui is also highlighting its SEKURE reagent kits, which offer liquid-stable technology, strong performance, proven reliability, and comprehensive support services. Calibrators, controls, and linearity materials are also on display to complement instrument-based testing.

Sekisui is also prominently featuring point-of-care and home-testing solutions at MEDICA 2025. The OSOM brand extends into home-use products, including antigen- and molecular-based kits for COVID-19 and other respiratory pathogens. Sekisui also introduces its Metrix molecular platform and the Acucy diagnostic reader, both designed to support instrument-enabled point-of-care workflows in decentralized settings.

High-quality enzymes and specialty biochemicals form another key part of the portfolio, with products tailored for a variety of applications, including pharmaceutical manufacturing, clinical chemistry reagents, and POC/biosensor devices. The company is also highlighting its raw materials for plastic vacuum blood-collection tubes and related pre-analytic systems, which are trusted by blood-collection tube manufacturers worldwide. Sekisui’s raw materials offer excellent performance characteristics that support stable, reliable serum generation with very low influence on clinical test results, contributing to more accurate diagnostics and improved patient outcomes.

Related Links:
Sekisui Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Silver Member
Connectivity Solution
EKF Link
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.